Jazz Pharmaceuticals To Acquire Developer Of Epilepsy Therapy Biotech Actio Biosciences For $820M Up Front And Up To $500M In Contingencies
Actio Biosciences' lead clinical asset is ABS-1230, a novel, first-in-class small molecule precision therapy KCNT1 ion channel inhibitor. KCNT1+ epilepsy is a rare genetic developmental and epileptic encephalopathy
Jazz Pharmaceuticals is buying a smaller company that made a new medicine for a rare type of epilepsy. This shows Jazz thinks this medicine could help patients and grow their business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.